Now that you’re MiSightÒ 1 day certificated and building myopia control as an integral part of your practice, here are some key steps to get you started and help boost your momentum.
Prescribe with Confidence Based on Strong, First-in-Class Science
MiSightÒ 1 day achieved a major milestone in 2019, when it received the first and only FDA approval* to slow myopia progression in children 8-12 years of age at the initiation of treatment±.
“Here we are, two years later, and it remains the only medical device that still has that indication for use,” says Michele Andrews, OD, Vice President, Professional & Government Affairs, CooperVision.
The compelling results behind the lens are based on the findings of a seven-year international study— the longest investigation of a soft lens in a pediatric patient population to date. In part 1 of the study, MiSightÒ 1 day reduced the rate of myopia progression by 59% on average 3,4҂
Understand Parent Motivators to Purchase
When it comes to their child’s eyesight, parents are concerned about their child’s future and want to do everything in their power to help them, in-market research suggests.5 And while data is important, parents’ treatment decisions are generally based on emotion rather than facts and figures.5
Parents also trust their ECP and cite their doctor’s recommendation as a primary motivator to act on treatment.5
“Don’t underestimate the value of the relationship you’ve built with your patients and the trust they have in you,” Dr. Andrews says.
*Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
± Only FDA approved soft contact lens designed for myopia control in the U.S.
‡ Fitted at 8-12 years of age at initiation of treatment.
҂Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates. Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight 1 day.
1. Compared to a single vision 1 day lens over a 3 year period. Chamberlain P, Peixoto-de-Matos SC, Logan N, et al. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019;96(8):556-567
2. Chamberlain P, Arumugam B, Jones D et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97.E-abstract: 200038.
3. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7-year findings. Optom Vis Sci 2021;98. E-abstract: 210049.
4. Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect, Optom Vis Sci 2021;98.E-abstract: 215130.
5. Decision Analyst. MiSight Parent Research. May 25-27, 2021.